Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer

OncoTargets and Therapy

关键词: egfr;    osimertinib;    non-small-cell lung cancer;    pancytopenia;    anemia;    neutropenia;    thrombocytopenia;    adverse events;   

DOI  :  

来源: DOAJ

【 摘 要 】

Pietro Di Marino,1 Cosima Chiapperino,1 Francesca Chiara Primavera,1 Maria Teresa Martino,1 Davide Brocco,2 Consiglia Carella,1 Antonino Grassadonia,3 Nicola Tinari,4 Michele De Tursi3 1Clinical Oncology Unit, SS Annunziata Hospital, Chieti, Italy; 2Department of Pharmacy, University G. D’Annunzio, Chieti- Pescara, Italy; 3Department of Innovative Technologies in Medicine and Dentistry, University G. D’Annunzio, Chieti- Pescara, Italy; 4Department of Medical, Oral and Biotechnological Sciences, University G. D’Annunzio, Chieti-Pescara, ItalyCorrespondence: Pietro Di Marino, Clinical Oncology Unit, SS Annunziata Hospital, Via Dei Vestini 5, Chieti, 66100, Italy, Tel [phone], Fax [phone], Email [e-mail]: Osimertinib is an irreversible tyrosine kinase inhibitor approved for the treatment of metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In clinical trials, osimertinib has exhibited excellent activity and less toxicity compared to gefitinib, erlotinib and standard chemotherapy.Case Presentation: Herein, we describe the case of a 69-year-old man who received first-line osimertinib for metastatic EGFR-mutated NSCLC. Suspected osimertinib-induced pancytopenia together with a partial treatment response was assessed after 10 days of therapy. Osimertinib was resumed at 40 mg daily a month later while the patient exhibited durable stable disease. No other adverse events occurred.Conclusion: In the current case, first-line treatment with osimertinib at 80 mg daily in a patient with EGFR-mutated NSCLC resulted in severe pancytopenia and a rapid treatment response. Dose reduction to 40 mg daily resulted in excellent activity without any further adverse events. Osimertinib could be safely resumed at a reduced dose even after pancytopenia.Keywords: adverse events, anemia, EGFR, neutropenia, non-small cell lung cancer, osimertinib, pancytopenia, thrombocytopenia

【 授权许可】

Unknown